Product Launch Information
Lupin Limited announced that its commercial partner Sandoz has launched RanluspecTM, Lupin's biosimilar Ranibizumab, across European markets, excluding Germany. The launch follows the European Commission approval of RanluspecTM in both vial and pre-filled syringe presentations.
Product Description and Indications
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. The approved indications for RanluspecTM include treatment of patients with:
- Neovascular (wet) age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
- Proliferative diabetic retinopathy
- Choroidal neovascularization
Executive Commentary
Thierry Volle, President EMEA and Emerging Markets, Lupin: "The launch of Ranluspec in Europe advances Lupin's strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region."
Dr. Cyrus Karkaria, President – Biotech Business, Lupin: "The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems."
Company Background
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has 15 manufacturing sites and 6 research centers globally, with over 26,000 professionals.